EUVIMEDEUVIMED entdecken
Open Access

Real-World Effectiveness of Biologic Therapies for Severe Asthma in a Diverse Middle Eastern Cohort: Evaluation of Longitudinal Symptom Improvement

Mohamed Abdul Kareem, Shumaila Z Naqvi, Syed Ammar Husain, Leon Gerard D Cruz, Syed Arshad Husain

Cureus · 24.03.2026

DOI: 10.7759/cureus.105804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 24.03.2026. Verfasst von Mohamed Abdul Kareem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, King's College Hospital, Dubai, ARE. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim Biologic therapies have transformed the management of severe asthma; however, real-world comparative data from ethnically diverse Middle Eastern populations remain limited. We evaluated the longitudinal effectiveness of benralizumab, dupilumab, mepolizumab, and tezepelumab in routine clinical practice in Dubai. This study aimed to evaluate the real-world performance and effectiveness of biologic therapies for respiratory diseases within the unique, high-dust environment and ethnically diverse patient population of Dubai, thereby providing data to bridge the gap between controlled clinical trials and routine clinical care outcomes.

Methods

This is a retrospective, single-center study of 47 adults with moderate-to-severe asthma receiving biologic therapy, contributing 141 longitudinal observations at baseline, six months, and 12 months. Baseline demographic and biomarker differences were assessed using chi-square and Kruskal-Wallis analyses with Dunn-Bonferroni correction. Longitudinal symptom trajectories (shortness of breath {SOB}, cough, wheeze) were analyzed using generalized estimating equations (GEE) with a binomial distribution and a logit link, accounting for repeated measures. Multivariable logistic regression was used to evaluate predictors of SOB resolution at 12 months.

Results

Significant baseline differences in ethnicity, smoking status, weight, BMI, fractional exhaled nitric oxide (FeNO), and eosinophil counts reflected phenotype-driven biologic selection. Despite this heterogeneity, time on biologic therapy was the only independent predictor of symptom improvement. Each visit was associated with significant reductions in SOB (B = -3.93, p < 0.001), cough (B = -2.28, p < 0.001), and wheeze (B = -1.75, p < 0.001). Biologic class was not associated with differential symptom trajectories. The logistic regression model for SOB resolution demonstrated moderate explanatory power (pseudo R² = 0.397; likelihood ratio test {LRT} p = 0.054), with no biologic showing superiority. Adherence rates were high and adverse events were infrequent.

Discussion

In this real-world, multi-ethnic cohort, biologic therapy was associated with substantial and progressive symptom improvement over 12 months, independent of drug class. These findings support the comparable effectiveness of currently available biologics and reinforce the importance of prolonged treatment durations and longitudinal assessment in the management of severe asthma.

Schlagwörter

Stichwörter der Autor:innen

a retrospective studybenralizumabbiologics therapydupilumabeosinophil countslongitudinal monitoringmepolizumabreal-world effectivenesssevere asthmatezepelumab

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, King's College Hospital, Dubai, ARE.
  • Department of Internal Medicine, Maidstone and Tunbridge Wells NHS Trust, Kent, GBR.
  • Department of Research and Innovation, Portsmouth Hospitals University NHS Trust, Portsmouth, GBR.
  • Department of Pulmonary Medicine, Al Zahra Hospital, Dubai, ARE.

Zitieren

APA

Kareem, M. A., Naqvi, S. Z., Ammar Husain, S., Cruz, L. G. D., & Husain, S. A. (2026). Real-World Effectiveness of Biologic Therapies for Severe Asthma in a Diverse Middle Eastern Cohort: Evaluation of Longitudinal Symptom Improvement. Cureus. https://doi.org/10.7759/cureus.105804

Vancouver

Kareem MA, Naqvi SZ, Ammar Husain S, Cruz LGD, Husain SA. Real-World Effectiveness of Biologic Therapies for Severe Asthma in a Diverse Middle Eastern Cohort: Evaluation of Longitudinal Symptom Improvement. Cureus. 2026. doi:10.7759/cureus.105804

BibTeX
@article{Kareem2026,
  author = {Kareem, Mohamed Abdul and Naqvi, Shumaila Z and Ammar Husain, Syed and Cruz, Leon Gerard D and Husain, Syed Arshad},
  title = {Real-World Effectiveness of Biologic Therapies for Severe Asthma in a Diverse Middle Eastern Cohort: Evaluation of Longitudinal Symptom Improvement},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.105804}
}
Kostenlos starten →